Centese, a Rosenman Innovator and MTVP portfolio company, is proud to announce several significant milestones in the development and clinical utilization of its groundbreaking Thoraguard System. Designed to transform surgical recovery, Thoraguard is approaching use in its 5,000th patient, marking a pivotal achievement in advancing patient care and surgical outcomes.
Centese continues to push the boundaries of innovation with the introduction of SmartCheck, an AI-powered product integrated into the Thoraguard System. SmartCheck leverages algorithms developed through clinical experience to optimize surgical outcomes with advanced decision support. By analyzing data and alerting clinicians in real-time, SmartCheck enhances efficiency, safety, and cost reduction, revolutionizing the field of surgical recovery.
Clinical data was recently presented at the Western Thoracic Surgical Association (WTSA) Annual Meeting underscores the critical role Thoraguard plays in improving surgical quality and reducing costs in lung cancer surgery.
Furthermore, these recent advancements build upon peer-reviewed data published in the Journal of Thoracic Disease. The study demonstrates that utilizing the Thoraguard System can lead to a remarkable one-day reduction in hospital length of stay compared to the current standard of care.
Centese continues to collaborate with leading healthcare institutions and professionals to expand the reach and impact of the Thoraguard System. The company’s relentless pursuit of innovation and its dedication to revolutionizing surgical recovery have positioned Centese as a leading innovator in the field of thoracic and cardiovascular surgery.